How to adjust the dosage of capmatinib

In the clinical application of capmatinib in the treatment of non-small cell lung cancer (NSCLC), the standard recommended dose is 400 mg twice daily, which can be taken on an empty stomach or with food. However, during treatment, dose adjustment is an important part of clinical management based on individual patient differences, drug reactions, and occurrence of adverse events, especially when drug-related side effects occur.

Pharmacokinetically, capmatinib is metabolized by the liver and therefore needs to be used with caution in patients with hepatic impairment. For patients with mild liver function impairment, the original dose can usually be maintained; however, in cases of moderate or severe liver function abnormalities, it is recommended that doctors reduce the dose appropriately based on the patient's transaminase (ALT/AST) and bilirubin levels to avoid drug accumulation in the body leading to increased toxicity.

When patients experience serious adverse reactions such as interstitial lung disease, severe rash, edema, elevated liver enzymes, etc., the use of capmatinib should be temporarily interrupted, and a decision should be made based on the severity of the symptoms whether to reduce the dose or permanently discontinue the drug. If symptoms are relieved, in most cases, administration can be restarted at a lower dose (such as 200 mg or 250 mg twice daily) and gradually returned to the maximum tolerated dose.

In addition, dose adjustments may also be required if patients are concurrently taking drugs that may affect the metabolism of capmatinib (such as strongCYP3A4 inhibitors or inducers). Such drugs may enhance or weaken the activity of capmatinib in the body, thereby affecting the therapeutic efficacy and safety. Therefore, it is recommended that patients should consult a doctor or pharmacist if they need to combine other drugs while taking the drug to ensure that interactions are properly managed.

In summary, capmatinib dose adjustment needs to be comprehensively evaluated based on clinical response, liver function status, and concomitant medications. Its personalized treatment strategy is an important means to ensure efficacy, safety and compliance, and is also an important embodiment of the concept of precision medicine.

Reference materials:https://www.drugs.com/mtm/capmatinib.html